Hullock Katie, O'Cathain Alicia, Sampson Fiona, Woodward Jonathan, Coates Elizabeth, Stavroulakis Theocharis, White Sean M, White David, Norman Paul, McDermott Christopher
Sheffield Clinical Trials Research Unit (CTRU), Sheffield Centre for Health and Related Research, The University of Sheffield, Sheffield, UK.
Sheffield Centre of Health and Related Research, The University of Sheffield, Sheffield, UK.
Health Expect. 2025 Oct;28(5):e70417. doi: 10.1111/hex.70417.
To explore intervention fidelity and experiences of using a new intervention designed to optimise calorie intake in people with amyotrophic lateral sclerosis (ALS).
A mixed-methods process evaluation was conducted alongside an ongoing randomised controlled trial across 15 ALS specialist centres in the United Kingdom. Data collection included 146 healthcare professional-completed fidelity checklists, audio recordings of 5 intervention sessions, and qualitative interviews with 32 healthcare professionals, patients and informal caregivers.
Intervention fidelity was high (88%: 1059/1204 items completed by healthcare professionals). Healthcare professionals, patients and informal caregivers within the sample recognised the intervention's value and engaged with it. Patients were motivated to use the intervention because they believed it could slow disease progression, and it gave them a sense of control. Despite challenges with the intervention, including patient concerns about weight gain and physical limitations in food preparation and consumption, patients in this sample remained committed to using the intervention. However, healthcare professionals suggested that these challenges may have negatively influenced trial recruitment and retention. Caregivers played a crucial role in supporting patients emotionally and physically, helping them to adhere to the intervention.
The intervention was feasible to implement and was delivered with fidelity. While patient engagement in this sample was strong, the intervention usability may be time-limited as physical function declines. Therefore, the intervention may be best suited for those with slower-progressing ALS who can manage the intervention and dietary changes. Moving forward, continued evaluation is needed to assess effectiveness and explore subgroup differences based on ALS type (slow vs. fast progressing).
PPI was integral to the process evaluation. PPI members reviewed key study documents, including the Participant Information Sheet and consent forms, leading to participant materials that were clear and easily understood. They also participated in developing the intervention.
IRAS ID 275949, ISRCTN30588041.
探讨一种旨在优化肌萎缩侧索硬化症(ALS)患者热量摄入的新干预措施的干预保真度及使用体验。
在英国15个ALS专科中心进行一项正在进行的随机对照试验的同时,开展了一项混合方法的过程评估。数据收集包括146份由医疗保健专业人员填写的保真度检查表、5次干预课程的音频记录,以及对32名医疗保健专业人员、患者和非正式照护者的定性访谈。
干预保真度较高(88%:医疗保健专业人员完成了1204项中的1059项)。样本中的医疗保健专业人员、患者和非正式照护者认可该干预措施的价值并参与其中。患者有动力使用该干预措施,因为他们认为它可以减缓疾病进展,并且能给他们一种掌控感。尽管该干预措施存在一些挑战,包括患者对体重增加的担忧以及食物准备和食用方面的身体限制,但该样本中的患者仍致力于使用该干预措施。然而,医疗保健专业人员表示,这些挑战可能对试验招募和留存产生了负面影响。照护者在为患者提供情感和身体支持、帮助他们坚持干预方面发挥了关键作用。
该干预措施实施可行且保真度良好。虽然该样本中的患者参与度较高,但随着身体功能下降,干预措施的可用性可能受时间限制。因此,该干预措施可能最适合那些病情进展较慢、能够管理干预措施和饮食变化的ALS患者。展望未来,需要持续评估以评估有效性,并根据ALS类型(进展缓慢与进展快速)探索亚组差异。
公众及患者参与(PPIE)贡献:PPI是过程评估不可或缺的部分。PPI成员审查了关键研究文件,包括参与者信息表和同意书,从而形成了清晰易懂的参与者材料。他们还参与了干预措施的制定。
IRAS编号275949,ISRCTN编号30588041。